Theratechnologies to sell Egrifta in South Korea
2015-08-31 16:30 ET - News Release Shares issued 65,615,603 TH Close 2015-08-28 C$ 2.28 Mr. Denis Boucher reports THERATECHNOLOGIES ANNOUNCES COMMERCIALIZATION AGREEMENT FOR TESAMORELIN IN SOUTH KOREA Theratechnologies Inc. has concluded an agreement with BL&H Co. Ltd. for the distribution and commercialization of Egrifta (tesamorelin for injection) for the treatment of HIV-associated lipodystrophy in South Korea. Under the terms of this agreement, BL&H will be responsible to conduct all regulatory activities required to obtain marketing approval for Egrifta in South Korea. Until then, BL&H intends to distribute Egrifta in the territory through named patient sales programs. Theratechnologies will manufacture and supply Egrifta to BL&H at a predetermined transfer price. The agreement has a 10-year term. "We are thrilled of our association with BL&H, which has a fast-growing portfolio of specialty products in South Korea. This agreement gives us a great opportunity to enter a new market over a short time frame. One objective of our 2015 business plan is finding partners to distribute Egrifta in additional territories. Today's announcement brings us closer to achieving this goal, and it represents another significant step towards bringing shareholder value through the realization of the full commercial potential of Egrifta," said Luc Tanguay, president and chief executive officer of Theratechnologies. BL&H is a privately owned company based in Seoul, South Korea. It is a leading distributor of pharmaceuticals and hospital-based products and services in South Korea. We seek Safe Harbor.